Vima raised a $40 million extension to its Series A, taking total financing to $100 million to complete two Phase II trials in isolated dystonia and Parkinson’s disease. Investors in the tranche included Atlas Venture, Frazier Life Sciences, Access Industries and Canaan Partners. Vima’s lead candidate VIM0423 pairs a muscarinic receptor antagonist with bethanechol to mitigate peripheral side effects, and the company said the new capital will support late‑stage clinical work and regulatory engagement for movement disorder indications.